Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients - PubMed (original) (raw)
Clinical Trial
. 2008 Dec 15;205(1-2):113-25.
doi: 10.1016/j.jneuroim.2008.09.004. Epub 2008 Oct 23.
Affiliations
- PMID: 18950872
- DOI: 10.1016/j.jneuroim.2008.09.004
Clinical Trial
Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients
Bianca Weinstock-Guttman et al. J Neuroimmunol. 2008.
Abstract
Purpose: To characterize gene expression in multiple sclerosis (MS) patients after the first dose and chronic dosing of 30 microg, once weekly, intramuscular interferon-beta1a (IFN-beta) and to delineate the pharmacogenomic differences between Good Responders and Partial Responders to IFN-beta therapy.
Methods: The treatment responses after the first IFN-beta dose and chronic IFN-beta dosing were assessed in 22 relapsing MS patients (17 females, 5 males; average age: 41.5+/-SD 10.4 years). Gene expression profiles in peripheral blood mononuclear cells were obtained prior to treatment and at 1, 2, 4, 8, 24, 48, 120, 168 h after the first IFN-beta dose and at 1, 6 and 12 months after chronic dosing with once-weekly 30 microg IFN-beta-1a intramuscularly. Repeated measures statistics with false discovery rate control were used. The functional characteristics, biological pathways and transcription factor sites were analyzed.
Results: Of the 1000 genes modulated following the first dose and upon chronic dosing of IFN-beta in MS patients, approximately 35% were up-regulated and 65% were down- regulated; the percentage of modulated genes in common was approximately 50%. The expression of the pharmacodynamic mRNA markers of IFN-beta effect showed differences in time profiles for the Good Responder and Partial Responders to IFN-beta therapy and the Jak-STAT, TNFRSF10B, IL6, TGFbeta, retinoic acid and CDC42 pathways were differentially modulated. The patients with side effects to therapy showed differences in the TGFbeta1, IFNG/STAT3 and TNF pathways.
Conclusions: Gene expression is a valuable tool for understanding the molecular mechanisms of IFN-beta action in MS patients.
Similar articles
- Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD. Singh MK, et al. J Neurol Sci. 2007 Jul 15;258(1-2):52-9. doi: 10.1016/j.jns.2007.02.034. Epub 2007 Apr 30. J Neurol Sci. 2007. PMID: 17467740 - Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
Durelli L. Durelli L. J Neurol. 2003 Dec;250 Suppl 4:IV9-IV14. doi: 10.1007/s00415-003-1403-7. J Neurol. 2003. PMID: 14712396 Review. - Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
Cristiano E. Cristiano E. Int J Clin Pract Suppl. 2002 Sep;(131):3-7. Int J Clin Pract Suppl. 2002. PMID: 12564806 Review.
Cited by
- Interferon β for Multiple Sclerosis.
Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B. Jakimovski D, et al. Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032003. doi: 10.1101/cshperspect.a032003. Cold Spring Harb Perspect Med. 2018. PMID: 29311124 Free PMC article. Review. - Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
Magner WJ, Weinstock-Guttman B, Rho M, Hojnacki D, Ghazi R, Ramanathan M, Tomasi TB. Magner WJ, et al. J Neuroimmunol. 2016 Mar 15;292:68-78. doi: 10.1016/j.jneuroim.2016.01.009. Epub 2016 Jan 21. J Neuroimmunol. 2016. PMID: 26943961 Free PMC article. - Thyroid hormone alleviates demyelination induced by cuprizone through its role in remyelination during the remission period.
Zhang M, Zhan XL, Ma ZY, Chen XS, Cai QY, Yao ZX. Zhang M, et al. Exp Biol Med (Maywood). 2015 Sep;240(9):1183-96. doi: 10.1177/1535370214565975. Epub 2015 Jan 10. Exp Biol Med (Maywood). 2015. PMID: 25577802 Free PMC article. - Systems approaches to human autoimmune diseases.
Banchereau R, Cepika AM, Pascual V. Banchereau R, et al. Curr Opin Immunol. 2013 Oct;25(5):598-605. doi: 10.1016/j.coi.2013.08.005. Epub 2013 Sep 18. Curr Opin Immunol. 2013. PMID: 24055331 Free PMC article. Review. - Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells.
Henig N, Avidan N, Mandel I, Staun-Ram E, Ginzburg E, Paperna T, Pinter RY, Miller A. Henig N, et al. PLoS One. 2013 Apr 23;8(4):e62366. doi: 10.1371/journal.pone.0062366. Print 2013. PLoS One. 2013. PMID: 23626809 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous